G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call Transcript

Jack Bailey: Yes.

Raj Malik: Okay. Maybe I can talk from a clinical data perspective and then Jack can talk about timing. So obviously we’re looking for the survival data, which we expect the early data in 2024. So that in the first quarter, I should say, and that will really give us directionally whether this is something we would want to pursue. And then I’ll leave it to Jack for the timing.

Jack Bailey: Yes. Thanks, Troy. Yes, I mean it’s going to obviously depend on the readout itself. But we will certainly look for different avenues if the data is compelling to be able to pursue that. So I would just say stay tuned and let’s see what the data shows.

Troy Langford: Okay. Great. Thanks for the color. And then just one other more, I guess, logistical question. Can you all just provide any more color on the one-time inventory reserve for potential product obsolescence that you all referred to in the press release issued this morning? And apologies if you mentioned it in the prepared remarks and I missed it.

John Umstead: No. Thanks, Troy. So what it is, obviously we had mentioned lowering our guidance. We’re taking a conservative approach in how we look at our inventory reserves. It’s a one-time non-cash impact to the P&L and obviously something we’ll continue to monitor. But we feel like it was a conservative approach for it at this point in the balance sheet.

Troy Langford: Okay. Great. Thanks for taking our question.

Operator: Thank you for your questions. I am showing no further questions at this time. I would now like to turn it back to Jack Bailey for closing remarks.

Jack Bailey: Thank you, operator. And as always, I look forward to keeping all of you updated on our progress. Thank you for joining us today. We’ll be in touch. Thank you.

Operator: Thank you for your participation in today’s conference. This does conclude the program, and you may now disconnect.